Top

Published in:

01-07-2016 | Original Article

Inhibition of proliferation and induction of apoptosis in RB116 retinoblastoma cells by afatinib treatment

Authors: Wei-jiao Zhan, Jian-feng Zhu, Long-mei Wang

Published in: Tumor Biology | Issue 7/2016

Abstract

The present study investigates the effect of afatinib on the growth, induction of apoptosis in RB116 cells, and reduction of carcinoma growth in the mice transplanted with RB116 cells. The results from MTT assay revealed that afatinib inhibited the growth of RB116 cells in a dose-dependent manner. Proliferation of RB116 cells was reduced to 64 % on treatment with 200 μM concentration of afatinib after 48 h. Afatinib treatment of RB116 cells at 200 μM concentration induced apoptosis and necrosis in 49.7 and 9.4 %, respectively, after 48 h. In the RB116-transplanted mice, treatment with afatinib at 10-mg/kg doses for 45 days caused a significant (p < 0.005) reduction in the tumor volume compared to the control group. The tissue lysates of the mice containing RB116 transplant showed a significant decrease in the expressions of Ki67 and p53 in the afatinib treatment group after 45 days. However, the expression of caspase-3 was increased and of Bcl-2 remained unaltered on treatment with afatinib. Measurement of the body weight of afatinib-treated animals showed no reduction during the study. Thus, afatinib can be of therapeutic value for the treatment of retinoblastoma.

Albert DM. Historic review of retinoblastoma. Ophthalmology. 1987;94:654–62.CrossRefPubMed

Shields JA, Shields CL. Current management of retinoblastoma. Mayo Clin Proc. 1994;69:50–6.CrossRefPubMed

Bishop JO, Madsen EC. Retinoblastoma; review of the current status. Surv Ophthalmol. 1975;19:342–66.PubMed

Yanagisawa T. Systemic chemotherapy as a new conservative treatment for intraocular retinoblastoma. Int J Clin Oncol. 2004;9:13–24.CrossRefPubMed

Rodriguez-Galindo C, Wilson MW, Haik BG, Merchant TE, Billups CA, Shaha N, et al. Treatment of intraocular retinoblastoma with vincristine and carboplatin. J Clin Oncol. 2003;21:2019–25.CrossRefPubMed

Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK, Batra SK. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16:15–31.CrossRefPubMedPubMedCentral

Zhang H, Berezov A, Wang Q, et al. ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest. 2007;117:2051–8.CrossRefPubMedPubMedCentral

Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2:127–37.CrossRefPubMed

Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene. 2008;27:4702–11.CrossRefPubMedPubMedCentral

10.

Harbeck N, Solca F, Gauler TC. Preclinical and clinical development of afatinib: a focus on breast cancer and squamous cell carcinoma of the head and neck. Future Oncol. 2014;10:21–40.CrossRefPubMed

11.

Tsai YC, Yeh CH, Tzen KY, Ho PY, Tuan TF, Pu YS, et al. Targeting epidermal growth factor receptor/human epidermal growth factor receptor 2 signalling pathway by a dual receptor tyrosine kinase inhibitor afatinib for radiosensitisation in murine bladder carcinoma. Eur J Cancer. 2013;49:1458–66.CrossRefPubMed

12.

Quesnelle KM, Grandis JR. Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance. Clinical Cancer Research. 2011;17:5935–44.CrossRefPubMedPubMedCentral

13.

Greulich H, Kaplan B, Mertins P, Chen TH, Tanaka KE, Yun CH, et al. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ErbB2. Proc Natl Acad Sci USA. 2012;109:14476–81.CrossRefPubMedPubMedCentral

14.

Cardillo MR, Castagna G, Memeo L, De Bernardinis E, Di Silverio F. Epidermal growth factor receptor, MUC-1 and MUC-2 in bladder cancer. J Exp Clin Cancer Res. 2000;19:225–33.PubMed

15.

Caner V, Turk NS, Duzcan F, et al. No strong association between HER-2/neu protein overexpression and gene amplification in high-grade invasive urothelial carcinomas. Pathol Oncol Res. 2008;14:261–6.CrossRefPubMed

16.

Kiyoshima K, Oda Y, Kinukawa N, Naito S, Tsuneyoshi M. Overexpression of laminin-5 gamma2 chain and its prognostic significance in urothelial carcinoma of urinary bladder: association with expression of cyclooxygenase 2, epidermal growth factor receptor [corrected] and human epidermal growth factor receptor [corrected] 2. Hum Pathol. 2005;36:522–30.CrossRefPubMed

17.

Mori H, Honda K, Ishida R, Nohira T, Tomoda A. Antitumor activity of 2-amino-4,4α-dihydro-4α,7-dimethyl-3H- phenoxazine-3-one against Meth A tumor transplanted into BALB/c mice. Anticancer Drugs. 2000;11:653–7.CrossRefPubMed

18.

Shimamoto T, Tomoda A, Ishida R, Ohyashiki K. Antitumor effect of a novel derivative on human leukemia cell lines in vivo and in vitro. Clin Cancer Res. 2001;7:704–8.PubMed

19.

Koshibu-Koizumi J, Akazawa M, Iwamoto T, Takasaki M, Mizuno F, Kobayashi R, et al. Antitumor activity of a phenoxazine compound, 2-amino-4,4α-dihydro- 4α,7-dimethyl-3H-phenoxazine-3-one against human B cell and T cell lymphoblastoid cell lines: induction of mixed types of cell death apoptosis and necrosis. J Cancer Res Clin Oncol. 2002;128:363–8.CrossRefPubMed

20.

Healy E, Angus B, Lawrence CM, Rees JL. Prognostic value of Ki67 antigen expression in basal cell carcinomas. Br J Dermatol. 1995;133:737–41.CrossRefPubMed

21.

Lustosa SA, Logullo A, Artigiani R, Saad SS, Goldenberg A, Matos D. Analysis of the correlation between p53 and Bcl-2 expression with staging and prognosis of the colorectal adenocarcinoma. Acta Cir Bras. 2005;20:353–7.CrossRefPubMed

Title: Inhibition of proliferation and induction of apoptosis in RB116 retinoblastoma cells by afatinib treatment
Authors: Wei-jiao Zhan
Jian-feng Zhu
Long-mei Wang
Publication date: 01-07-2016
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 7/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-4768-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2016

High expression of constitutive photomorphogenic 1 (COP1) is associated with poor prognosis in bladder cancer

Expression of Pim-3 in colorectal cancer and its relationship with prognosis

Overexpression of ADAMTS5 can regulate the migration and invasion of non-small cell lung cancer

Is cholesterol a mediator of cold-induced cancer?

Monitoring the treatment outcome in endometrial cancer patients by CEA and TATI

Prognostic impact and potential interaction of EGFR and c-Met in the progression of esophageal squamous cell carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer